Suppr超能文献

对新开始使用自注射或口服疾病修正药物治疗的多发性硬化症患者的依从性评估。

An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug.

作者信息

Munsell Michael, Frean Molly, Menzin Joseph, Phillips Amy L

机构信息

Boston Health Economics, Inc., Waltham, MA, USA.

Health Economics & Outcomes Research, EMD Serono Inc., Rockland, MA, USA.

出版信息

Patient Prefer Adherence. 2016 Dec 30;11:55-62. doi: 10.2147/PPA.S118107. eCollection 2017.

Abstract

OBJECTIVE

As the multiple sclerosis (MS) disease-modifying drug (DMD) treatment options have expanded to include oral therapies, it is important to understand whether route of administration is associated with DMD adherence. The objective of this study was to compare adherence to DMDs in patients with MS newly initiating treatment with a self-injectable versus an oral DMD.

METHODS

This retrospective database study used IMS Health Real World Data Adjudicated Claims - US data between July 1, 2010 and June 30, 2014. Adherence was measured by medication possession ratio (MPR), calculated as the total number of treated days divided by the total number of days from the first treated day until the end of 12-month follow-up. A binary measure representing adherence (MPR ≥0.8) versus nonadherence (MPR <0.8) to therapy was used. Logistic regression evaluated the likelihood of adherence to index DMD type (self-injectable vs oral). Covariates included patient baseline characteristics (ie, age, sex, comorbidities) and index DMD type.

RESULTS

The analysis included 7,207 self-injectable and 1,175 oral DMD-treated patients with MS. In unadjusted analyses, the proportion of patients adherent to therapy (MPR ≥0.8) did not differ significantly between the self-injectable (54.1%) and the oral DMD cohorts (53.0%; =0.5075). After controlling for covariates, index DMD type was not a significant predictor of adherence (odds ratio [OR] 1.062; 95% confidence interval [CI]: 0.937-1.202; =0.3473). Higher likelihood of adherence was associated with male sex (OR 1.20; 95% CI: 1.085-1.335; =0.0005) and age groups older than 18-34 years (ORs 1.220-1.331; <0.01). Depression was associated with a lower likelihood of adherence (OR 0.618; 95% CI: 0.511-0.747; <0.0001).

CONCLUSION

Male sex and age older than 18-34 years were significantly associated with a higher likelihood of adherence, while depression was associated with a lower likelihood of adherence. Index DMD type, stratified by the route of administration (self-injectable vs oral DMD), was not a significant predictor of DMD adherence.

摘要

目的

随着多发性硬化症(MS)疾病修正药物(DMD)治疗选择已扩展至包括口服疗法,了解给药途径是否与DMD依从性相关很重要。本研究的目的是比较新开始使用自我注射型DMD与口服DMD治疗的MS患者对DMD的依从性。

方法

这项回顾性数据库研究使用了艾美仕市场研究公司(IMS Health)真实世界数据判定索赔——2010年7月1日至2014年6月30日期间的美国数据。依从性通过药物持有率(MPR)衡量,计算方法为治疗天数总数除以从首次治疗日至12个月随访结束的天数总数。使用了一种表示对治疗依从(MPR≥0.8)与不依从(MPR<0.8)的二元指标。逻辑回归评估了对索引DMD类型(自我注射型与口服型)依从的可能性。协变量包括患者基线特征(即年龄、性别、合并症)和索引DMD类型。

结果

分析纳入了7207例接受自我注射型DMD治疗和1175例接受口服DMD治疗的MS患者。在未调整分析中,自我注射型DMD组(54.1%)和口服DMD组(53.0%;P=0.5075)中治疗依从(MPR≥0.8)的患者比例无显著差异。在控制协变量后,索引DMD类型不是依从性的显著预测因素(比值比[OR]1.062;95%置信区间[CI]:0.937 - 1.202;P=0.3473)。依从可能性较高与男性性别(OR 1.20;95% CI:1.085 - 1.335;P=0.0005)以及年龄大于18 - 34岁的年龄组相关(OR为1.220 - 1.331;P<0.01)。抑郁症与较低的依从可能性相关(OR 0.618;95% CI:0.511 - 0.747;P<0.0001)。

结论

男性性别和年龄大于18 - 34岁与较高的依从可能性显著相关,而抑郁症与较低的依从可能性相关。按给药途径分层的索引DMD类型(自我注射型与口服DMD)不是DMD依从性的显著预测因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89e2/5221550/c21f53055da2/ppa-11-055Fig1.jpg

相似文献

2
Real-world persistence and adherence of ofatumumab versus oral and injectable disease-modifying therapies in patients with multiple sclerosis.
Mult Scler Relat Disord. 2024 Nov;91:105888. doi: 10.1016/j.msard.2024.105888. Epub 2024 Sep 12.
4
First-line disease-modifying drugs in relapsing-remitting multiple sclerosis: an Italian real-life multicenter study on persistence.
Curr Med Res Opin. 2018 Oct;34(10):1803-1807. doi: 10.1080/03007995.2018.1451311. Epub 2018 Apr 12.
8
Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study.
PLoS One. 2015 Jul 27;10(7):e0133279. doi: 10.1371/journal.pone.0133279. eCollection 2015.
9
Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis.
Clin Ther. 2020 Nov;42(11):2136-2147.e3. doi: 10.1016/j.clinthera.2020.09.014. Epub 2020 Nov 5.

引用本文的文献

1
Adherence to therapeutic recommendation in relapsing-remitting multiple sclerosis patients.
Front Immunol. 2025 Jun 26;16:1545430. doi: 10.3389/fimmu.2025.1545430. eCollection 2025.
2
Treatment Adherence in a Large Cohort of Turkish Multiple Sclerosis Population.
Neurol Sci. 2025 Jun;46(6):2737-2746. doi: 10.1007/s10072-025-08055-4. Epub 2025 Feb 19.
3
Costs of Potential Medication Wastage Due to Switching Treatment Among People With Multiple Sclerosis.
J Health Econ Outcomes Res. 2024 Oct 28;11(2):103-108. doi: 10.36469/001c.123336. eCollection 2024.
5
The patient-reported wearing-off phenomenon with monoclonal antibody treatments for multiple sclerosis.
Mult Scler J Exp Transl Clin. 2024 May 6;10(2):20552173241251707. doi: 10.1177/20552173241251707. eCollection 2024 Apr-Jun.
7
Psychometric evaluation of the 5-item Medication Adherence Report Scale questionnaire in persons with multiple sclerosis.
PLoS One. 2024 Mar 4;19(3):e0294116. doi: 10.1371/journal.pone.0294116. eCollection 2024.
9
Adherence to subcutaneous interferon beta-1a treatment among patients with relapsing multiple sclerosis: the MAIN-MS study.
Front Neurol. 2023 Nov 28;14:1257455. doi: 10.3389/fneur.2023.1257455. eCollection 2023.
10
Factors Associated With Disease-Modifying Therapy Adherence and Persistence in Multiple Sclerosis: A Scoping Literature Review.
Int J MS Care. 2023 Sep-Oct;25(5):188-195. doi: 10.7224/1537-2073.2021-139. Epub 2023 Sep 14.

本文引用的文献

1
Adherence and persistence to drug therapies for multiple sclerosis: A population-based study.
Mult Scler Relat Disord. 2016 Jul;8:78-85. doi: 10.1016/j.msard.2016.05.006. Epub 2016 May 7.
2
Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study.
Mult Scler. 2017 Apr;23(4):588-596. doi: 10.1177/1352458516657440. Epub 2016 Jul 11.
4
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study.
Expert Opin Drug Deliv. 2016 Jun;13(6):799-805. doi: 10.1517/17425247.2016.1158161. Epub 2016 Mar 12.
6
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
Mult Scler. 2016 Apr;22(4):520-32. doi: 10.1177/1352458515594041. Epub 2015 Jul 21.
7
Treatment adherence and transitioning youth in pediatric multiple sclerosis.
Mult Scler Relat Disord. 2014 Nov;3(6):689-95. doi: 10.1016/j.msard.2014.09.088.
8
A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview.
Mult Scler. 2015 Mar;21(3):263-81. doi: 10.1177/1352458514564491. Epub 2015 Jan 26.
9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验